A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Glaukos Submits NDA for Epioxa Epi-On Crosslinking Treatment
Author: Joan McKenna
Glaukos, of Aliso Viejo, California, reported Dec. 23 that it had submitted its new drug application to the US FDA for Epioxa, an epi-on version of the company’s iLink corneal crosslinking therapy, for the treatment of keratoconus. Epioxa is designed to reduce the treatment’s procedure and recovery time and improve patient comfort. Glaukos’ first-generation iLink procedure gained US approval in April 2016 under developer Avedro. It is an epi-off crosslinking procedure that takes roughly an ho...
Purchasing one of the following products will open up access to this article's content, which is also available in each comprehensive report/subscription.